A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back, according to results of a major study released Thursday by drugmakers Moderna and Merck. (AP Video/Lekan Oyekanmi; Production/Shelby Lum)
Subscribe: http://smarturl.it/AssociatedPress
Read more: https://apnews.com
This video may be available for archive licensing via https://newsroom.ap.org/home
A first-of-its-kind cancer vaccine is helping significantly reduce the chances that melanoma patients' tumors return.
A first-of-its-kind cancer vaccine is helping significantly reduce the chances that melanoma patients' tumors return.
Moderna shares plunged as much as 25% after partial clinical trial data leaked for its personalized cancer vaccine developed with Merck, despite the full results showing…
Discussion (0)
No comments yet. Start the conversation!